At Apertor we have developed a new class of therapeutics to address one of the toughest challenges in drug discovery — selective disruption of disease-causing protein-protein interactions (PPIs). Apertor’s Interceptors are designed to selectively disrupt protein complexes via proximity induction by recruiting an abundantly expressed protein naturally found in cancerous cells patient’s own proteins to safely and effectively block PPIs . Using our synthetic biology platform technology to invent and develop proprietary Interceptors, Apertor’s robust pipeline is unlocking new treatment possibilities for cancer patients.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Alameda, Ca, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.apertorpharma.com
- HQ
- Alameda, CA
Apertor Pharmaceuticals Questions
Apertor Pharmaceuticals's website is http://www.apertorpharma.com
Apertor Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/apertor-pharmaceuticals
Apertor Pharmaceuticals has
12 employees.
View email and phone details for 12
employees at Apertor Pharmaceuticals.
Apertor Pharmaceuticals's industry is
Biotechnology Research
Apertor Pharmaceuticals's top competitors are
Xaira Therapeutics,
Ascidian Therapeutics,
Initial Therapeutics,
Nine Square Therapeutics,
Maze Therapeutics,
Atp (Apple Tree Partners),
Evercrisp Biosciences,
Rezo Therapeutics,
Circle Pharma, Inc.,
Deep Apple Therapeutics.
Apertor Pharmaceuticals's categories are Biotechnology Research
Apertor Pharmaceuticals's founding year is 2020
